Emergingbiotechs - emergingbiotechs.com
General Information:
Latest News:
Medicare and Medicaid Waste in Focus as CMS Administrator Departs Position 8 Dec 2011 | 11:45 pm
The New York Times published an article this past weekend titled, “Health Official Takes Parting Shot at Waste.” Written by Robert Pear, the article focuses on commentary from Dr. Donald M. Berwick, ...
22nd Century Rival Star Scientific Takes Public Pummeling 16 Jul 2011 | 05:26 am
In the continuing battle between “pharma-tobacco” companies, Star Scientific, Inc. (Nasdaq: CIGX) took a recent and severe public drubbing in a two-part article at SeekingAlpha.com. On the contrary, 2...
Unilife Commences Unifill Syringe Supply to Sanofi 16 Jul 2011 | 03:53 am
Unilife Begins the Supplying of Product to Sanofi Unilife Corp. (NASDAQ: UNIS; Stock Twits: $UNIS) issued a significant piece of news today with the announcement that it has commenced the initial sup...
22nd Century Rival Star Scientific Takes Public Pummeling 16 Jul 2011 | 01:26 am
In the continuing battle between “pharma-tobacco” companies, Star Scientific, Inc. (Nasdaq: CIGX) took a recent and severe public drubbing in a two-part article at SeekingAlpha.com. On the contrary, 2...
Cardiology News: Cardiologist Need for Predictive Technology 30 Jun 2011 | 03:54 am
Common solutions for heart conditions are just that: common. This by no means devalues their importance, nor does it overvalue frequency of use. In fact, regarding the value proposition, the device...
The True Value of a SPA: An Inside Look at CorMedix, Inc. 30 Jun 2011 | 03:32 am
The granting of a Special Protocol Assessment (“SPA”) by the U.S. Food and Drug Administration is certainly not something to overlook. According to Wikipedia, a SPA “is a declaration from the Food an...
CorMedix Receives SPA from FDA for Deferiprone Phase 3 trial 25 Jun 2011 | 04:24 am
CorMedix (AMEX: CRMD) announced that it received a Special Protocol Assessment approval letter from the FDA on the design of a pivotal Phase 3 trial for Deferiprone. Deferiprone is indicated for Contr...
Former FDA Chief Kessler Urges Clampdown on Nicotine Levels; 22nd Century’s Rx-Cigs Meet the Mark 22 Jun 2011 | 08:18 pm
Botanical biotech and genetic engineering company 22nd Century Group, Inc. (OTCBB: XXII), whose proprietary technology enables genetic engineering of levels of nicotine and other alkaloids in the toba...
Former FDA Chief Kessler Urges Clampdown on Nicotine Levels; 22nd Century’s Rx-Cigs Meet the Mark 22 Jun 2011 | 04:18 pm
Botanical biotech and genetic engineering company 22nd Century Group, Inc. (OTCBB: XXII), whose proprietary technology enables genetic engineering of levels of nicotine and other alkaloids in the toba...
HEALTHCARE MEGATRENDS: Early Detection of At-Risk Heart Patients 10 Jun 2011 | 06:33 am
The heart attack epidemic inherited from the 20th century makes it difficult for most people to imagine a future in which heart attacks are much less of a threat. But progress is being made in early d...
